Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Nat Biotechnol. 2010 Apr;28(4):341-7. doi: 10.1038/nbt.1618. Epub 2010 Mar 28.
MicroRNAs (miRNAs) are increasingly implicated in the regulation of metastasis. Despite their potential as targets for anti-metastatic therapy, miRNAs have only been silenced in normal tissues of rodents and nonhuman primates. Therefore, the development of effective approaches for sequence-specific inhibition of miRNAs in tumors remains a scientific and clinical challenge. Here we show that systemic treatment of tumor-bearing mice with miR-10b antagomirs-a class of chemically modified anti-miRNA oligonucleotide-suppresses breast cancer metastasis. Both in vitro and in vivo, silencing of miR-10b with antagomirs significantly decreases miR-10b levels and increases the levels of a functionally important miR-10b target, Hoxd10. Administration of miR-10b antagomirs to mice bearing highly metastatic cells does not reduce primary mammary tumor growth but markedly suppresses formation of lung metastases in a sequence-specific manner. The miR-10b antagomir, which is well tolerated by normal animals, appears to be a promising candidate for the development of new anti-metastasis agents.
微小 RNA(miRNA)越来越多地参与转移的调控。尽管它们有可能成为抗转移治疗的靶点,但 miRNA 仅在啮齿动物和非人类灵长类动物的正常组织中被沉默。因此,开发有效的方法来特异性抑制肿瘤中的 miRNA 仍然是一个科学和临床挑战。在这里,我们表明,用 miR-10b 拮抗剂——一类化学修饰的抗 miRNA 寡核苷酸——对荷瘤小鼠进行系统治疗可抑制乳腺癌转移。无论是在体外还是体内,用拮抗剂沉默 miR-10b 可显著降低 miR-10b 水平并增加功能重要的 miR-10b 靶标 Hoxd10 的水平。用 miR-10b 拮抗剂处理携带高转移性细胞的小鼠不会减少原发性乳腺肿瘤的生长,但会以序列特异性方式显著抑制肺转移的形成。miR-10b 拮抗剂在正常动物中具有良好的耐受性,似乎是开发新型抗转移药物的有前途的候选药物。